JP2002523375A - 骨の靭性、及び、剛性を増し、骨折を減少させる方法 - Google Patents

骨の靭性、及び、剛性を増し、骨折を減少させる方法

Info

Publication number
JP2002523375A
JP2002523375A JP2000565916A JP2000565916A JP2002523375A JP 2002523375 A JP2002523375 A JP 2002523375A JP 2000565916 A JP2000565916 A JP 2000565916A JP 2000565916 A JP2000565916 A JP 2000565916A JP 2002523375 A JP2002523375 A JP 2002523375A
Authority
JP
Japan
Prior art keywords
bone
fracture
pth
stiffness
toughness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000565916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523375A5 (enExample
Inventor
ジャネット・エム・ホック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2002523375(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2002523375A publication Critical patent/JP2002523375A/ja
Publication of JP2002523375A5 publication Critical patent/JP2002523375A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Steroid Compounds (AREA)
JP2000565916A 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法 Pending JP2002523375A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9715198P 1998-08-19 1998-08-19
US60/097,151 1998-08-19
US9974698P 1998-09-10 1998-09-10
US60/099,746 1998-09-10
PCT/US1999/018961 WO2000010596A1 (en) 1998-08-19 1999-08-19 Method of increasing bone toughness and stiffness and reducing fractures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010244314A Division JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Publications (2)

Publication Number Publication Date
JP2002523375A true JP2002523375A (ja) 2002-07-30
JP2002523375A5 JP2002523375A5 (enExample) 2009-01-29

Family

ID=26792729

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000565916A Pending JP2002523375A (ja) 1998-08-19 1999-08-19 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010244314A Withdrawn JP2011021035A (ja) 1998-08-19 2010-10-29 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014061763A Expired - Lifetime JP6177718B2 (ja) 1998-08-19 2014-03-25 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2014204577A Withdrawn JP2015028065A (ja) 1998-08-19 2014-10-03 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2017124301A Withdrawn JP2017190332A (ja) 1998-08-19 2017-06-26 骨の靭性、及び、剛性を増し、骨折を減少させる方法

Country Status (32)

Country Link
US (2) US6977077B1 (enExample)
EP (3) EP1059933B1 (enExample)
JP (5) JP2002523375A (enExample)
KR (1) KR100454207B1 (enExample)
CN (1) CN1205997C (enExample)
AR (1) AR033639A1 (enExample)
AT (1) ATE231000T1 (enExample)
AU (1) AU746277B2 (enExample)
BR (1) BR9909445A (enExample)
CA (1) CA2325371C (enExample)
CO (1) CO5130020A1 (enExample)
CY (2) CY1113343T1 (enExample)
CZ (1) CZ301017B6 (enExample)
DE (2) DE15152726T1 (enExample)
DK (4) DK1059933T3 (enExample)
DZ (1) DZ2873A1 (enExample)
EA (1) EA003362B1 (enExample)
ES (4) ES2190244T3 (enExample)
HR (1) HRP20000755A2 (enExample)
HU (2) HU1200430D0 (enExample)
ID (1) ID29039A (enExample)
IL (2) IL138829A0 (enExample)
MY (1) MY129227A (enExample)
NO (2) NO323984B1 (enExample)
NZ (1) NZ507056A (enExample)
PE (1) PE20001089A1 (enExample)
PL (1) PL201688B1 (enExample)
PT (4) PT1059933E (enExample)
TR (1) TR200003455T2 (enExample)
TW (1) TW576747B (enExample)
UA (1) UA72205C2 (enExample)
WO (1) WO2000010596A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505883A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法
JP2008540522A (ja) * 2005-05-11 2008-11-20 ユニジーン・ラボラトリーズ・インコーポレーテッド 骨の形成および保存を促進するための方法
US7776826B2 (en) 2004-05-14 2010-08-17 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
JP2011021035A (ja) * 1998-08-19 2011-02-03 Eli Lilly & Co 骨の靭性、及び、剛性を増し、骨折を減少させる方法
WO2011030774A1 (ja) * 2009-09-09 2011-03-17 旭化成ファーマ株式会社 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
JP2021088606A (ja) * 2017-09-22 2021-06-10 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
WO2001022093A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
US7247609B2 (en) 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
MXPA06013168A (es) 2004-05-13 2007-05-15 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes de la hormona paratiroidea.
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008125655A1 (en) 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
US20110137243A1 (en) * 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US9457056B2 (en) * 2007-12-04 2016-10-04 Ben-Gurion University Of The Negev Research And Development Authority Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis
EP2227263A2 (en) 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9295663B2 (en) 2010-07-14 2016-03-29 Abbott Cardiovascular Systems Inc. Drug coated balloon with in-situ formed drug containing microspheres
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
CN108195965B (zh) 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
JP2020506926A (ja) * 2017-02-01 2020-03-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 副甲状腺ホルモンと変性椎間板疾患の再生
CN111447943A (zh) 2018-10-29 2020-07-24 旭化成制药株式会社 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
GB2590692A (en) * 2019-12-24 2021-07-07 Corthotec Ltd Composition for improved bone fracture healing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07179358A (ja) * 1985-04-04 1995-07-18 General Hospital Corp:The 骨質量増加用医薬複合剤の投与用キット
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
JPH0873376A (ja) * 1994-09-07 1996-03-19 Asahi Chem Ind Co Ltd 骨粗鬆症治療薬
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
EP1283035A3 (en) * 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
JPH08310965A (ja) * 1995-05-16 1996-11-26 Chugai Pharmaceut Co Ltd 骨癒合促進剤
BR9812068A (pt) 1997-09-09 2000-09-26 Hoffmann La Roche Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US6907597B1 (en) 2000-10-13 2005-06-14 Ati International Srl Method and apparatus for constructing an executable program in memory
US6967759B2 (en) 2001-12-31 2005-11-22 Texas Instruments Incorporated Pulse width modulation sequence generation
JP5796714B2 (ja) 2012-01-13 2015-10-21 株式会社リコー 定着装置及び画像形成装置
EP2949301B1 (en) 2014-05-27 2018-04-18 The Procter and Gamble Company Absorbent core with curved and straight absorbent material areas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07179358A (ja) * 1985-04-04 1995-07-18 General Hospital Corp:The 骨質量増加用医薬複合剤の投与用キット
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6009033243, ＬＩＮＤＳＡＹ，Ｒ． ｅｔ ａｌ, "Ｒａｎｄｏｍｉｓｅｄ ｃｏｎｔｒｏｌｌｅｄ ｓｔｕｄｙ ｏｆ ｅｆｆｅｃｔ ｏｆ ｐａｒａｔｈｙｒｏｉｄ ｈｏｒｍｏｎｅ ｏｎ ｖｅｒｔｅｂｒａｌ−ｂｏｎｅ ｍａｓｓ ａｎｄ ｆｒａｃｔｕｒｅ ｉｎｃ", Ｌａｎｃｅｔ, 1997, Ｖｏｌ．３５０， Ｎｏ．９０７７, ｐ．５５０−５ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011021035A (ja) * 1998-08-19 2011-02-03 Eli Lilly & Co 骨の靭性、及び、剛性を増し、骨折を減少させる方法
JP2007505883A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク ２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法
US7776826B2 (en) 2004-05-14 2010-08-17 Unigene Laboratories, Inc. Method for fostering bone formation and preservation
JP2008540522A (ja) * 2005-05-11 2008-11-20 ユニジーン・ラボラトリーズ・インコーポレーテッド 骨の形成および保存を促進するための方法
WO2011030774A1 (ja) * 2009-09-09 2011-03-17 旭化成ファーマ株式会社 １回当たり１００～２００単位のｐｔｈが週１回投与されることを特徴とする、ｐｔｈ含有骨粗鬆症治療／予防剤
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
JP2021088606A (ja) * 2017-09-22 2021-06-10 旭化成ファーマ株式会社 安定性に優れるテリパラチド含有液状医薬組成物

Also Published As

Publication number Publication date
PL201688B1 (pl) 2009-04-30
DK1769804T3 (da) 2012-10-15
CZ301017B6 (cs) 2009-10-14
CO5130020A1 (es) 2002-02-27
DE69904918D1 (de) 2003-02-20
CA2325371C (en) 2004-08-17
US20050197294A1 (en) 2005-09-08
TW576747B (en) 2004-02-21
DK2907522T1 (da) 2015-10-19
ES2190244T3 (es) 2003-07-16
CN1308545A (zh) 2001-08-15
CZ20004134A3 (cs) 2001-08-15
US6977077B1 (en) 2005-12-20
ES2393200T3 (es) 2012-12-19
DK2266598T3 (en) 2017-05-15
HK1030545A1 (en) 2001-05-11
ES2549551T3 (es) 2017-11-27
PT2907522T (pt) 2017-10-23
EA003362B1 (ru) 2003-04-24
IL138829A (en) 2011-01-31
US7163684B2 (en) 2007-01-16
EP2266598B1 (en) 2017-02-22
PT1059933E (pt) 2003-06-30
HK1102496A1 (en) 2007-11-23
DK1059933T3 (da) 2003-04-07
CY1119552T1 (el) 2018-03-07
EP2907522A1 (en) 2015-08-19
CA2325371A1 (en) 2000-03-02
DE15152726T1 (de) 2015-12-10
UA72205C2 (uk) 2005-02-15
ES2549551T1 (es) 2015-10-29
CY1113343T1 (el) 2016-06-22
NO323984B1 (no) 2007-07-30
MY129227A (en) 2007-03-30
JP2011021035A (ja) 2011-02-03
ES2621653T3 (es) 2017-07-04
NO20072983L (no) 2000-11-24
PL343595A1 (en) 2001-08-27
DK2907522T3 (en) 2017-10-23
JP2015028065A (ja) 2015-02-12
JP6177718B2 (ja) 2017-08-09
JP2014139220A (ja) 2014-07-31
WO2000010596A1 (en) 2000-03-02
ID29039A (id) 2001-07-26
EP1059933B1 (en) 2003-01-15
JP2017190332A (ja) 2017-10-19
KR20010072763A (ko) 2001-07-31
PT2266598T (pt) 2017-05-02
NO20005947D0 (no) 2000-11-24
TR200003455T2 (tr) 2001-06-21
DE69904918T2 (de) 2003-11-13
NO20005947L (no) 2000-11-24
NZ507056A (en) 2003-10-31
IL138829A0 (en) 2001-10-31
PT1769804E (pt) 2012-11-13
HU1200430D0 (hu) 2001-11-28
HU230697B1 (hu) 2017-09-28
HK1212602A1 (en) 2016-06-17
AU746277B2 (en) 2002-04-18
CN1205997C (zh) 2005-06-15
ATE231000T1 (de) 2003-02-15
PE20001089A1 (es) 2000-11-04
HUP0101594A2 (hu) 2001-11-28
BR9909445A (pt) 2000-12-12
EP1059933A1 (en) 2000-12-20
EP2907522B1 (en) 2017-08-02
DZ2873A1 (fr) 2003-12-15
EA200001015A1 (ru) 2001-02-26
AR033639A1 (es) 2004-01-07
HUP0101594A3 (en) 2002-01-28
KR100454207B1 (ko) 2004-10-26
HRP20000755A2 (en) 2001-02-28
EP2266598A1 (en) 2010-12-29
AU5575099A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
JP6177718B2 (ja) 骨の靭性、及び、剛性を増し、骨折を減少させる方法
US7351414B2 (en) Method of reducing the risk of bone fracture
EP1295605A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
EP1769804A2 (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1037333A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1212602B (en) Method of increasing bone toughness and stiffness and reducing fractures
MXPA00009982A (en) Method of increasing bone toughness and stiffness and reducing fractures
HK1102496B (en) Hpth(1-34) for use in preventing or reducing the incidence or severity of vertebral and / or non vertebral fracture in a male human
HK1030545B (en) Use of parathyroide hormone consisting of aminoacid sequence 1-34 of human parathyroid hormone for reducing the risk of both vertebral and non vertebral bone fracture

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090727

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090727

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090727

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110104